Silexion Therapeutics (SLXN) EBITDA (2023 - 2026)
Silexion Therapeutics (SLXN) posted quarterly EBITDA of -$2.7 million for Q1 2026, down 66.61% year-over-year from -$8.2 million in Q1 2025, and up 37.61% quarter-over-quarter from -$4.4 million in Q4 2025.
Silexion Therapeutics (SLXN) EBITDA (2023 - 2026) Analysis & Trends
Silexion Therapeutics' EBITDA history runs 4 years deep, the most recent figure standing at -$2.7 million for Q1 2026.
- In Q1 2026, EBITDA fell 66.61% year-over-year to -$2.7 million; the TTM figure through Mar 2026 stood at -$12.7 million (up 1.85% YoY), while the FY2025 annual figure was -$11.6 million, up 7.47% from the prior year.
- EBITDA for Q1 2026 stood at -$2.7 million, up from -$4.4 million in the prior quarter.
- The five-year high for EBITDA was -$731000.0 in Q3 2023, with the low at -$8.0 million in Q3 2024.
- The 4-year median for EBITDA is -$1.8 million (2023), against an average of -$2.6 million.
- The sharpest annual moves came in 2024 and 2025: EBITDA plunged 999.32% in 2024, then soared 59.03% in 2025.
- Silexion Therapeutics' EBITDA stood at -$1.7 million in 2023, then retreated by 9.95% to -$1.9 million in 2024, then sank by 131.89% to -$4.4 million in 2025, then jumped by 37.61% to -$2.7 million in 2026.
- Business Quant data shows SLXN's EBITDA at -$2.7 million in Q1 2026, -$4.4 million in Q4 2025, and -$3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | 133.12 Mn |
| 10 | Silexion Therapeutics | 271,023.30 | -1.96 Mn | - | -3.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.68 Mn |
| Mar 31, 2026 | -2.75 Mn |
| Dec 31, 2025 | -4.41 Mn |
| Sep 30, 2025 | -3.29 Mn |
| Jun 30, 2025 | -2.28 Mn |
| Mar 31, 2025 | -1.65 Mn |
| Dec 31, 2024 | -1.90 Mn |
| Sep 30, 2024 | -8.04 Mn |
| Jun 30, 2024 | -1.39 Mn |
| Mar 31, 2024 | -1.25 Mn |
| Dec 31, 2023 | -1.73 Mn |
| Sep 30, 2023 | -731,000.00 |
| Jun 30, 2023 | -1.41 Mn |